Who Owns Novozymes Company?

Novozymes Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who owns Novozymes now that it merged into Novonesis?

The 2024 merger of Novozymes and Chr. Hansen created Novonesis, reshaping Danish biotech with a ~12.3 billion USD deal and a foundation-led ownership model that steers long-term research over short-term gains. Novonesis retains roots in Bagsværd and the Novo legacy.

Major ownership centers on the Novo Nordisk Foundation as the controlling anchor, complemented by global institutional investors and expanded public shareholders after the merger; see product insight: Novozymes Porter's Five Forces Analysis

Founders and Early Ownership of Novozymes trace directly to Novo Nordisk A/S; Novozymes was created via a strategic demerger in November 2000 with Steen Riisgaard appointed as its first CEO. The spin-off adopted a dual-class share structure mirroring the parent to preserve stability and governance continuity.

Origin via demerger

Novozymes emerged from Novo Nordisk’s enzyme division during the November 2000 spin-off, not as a standalone startup.

Leadership at launch

Steen Riisgaard led the new company as its first CEO, guiding early strategic and operational setup.

Share structure

The equity used a dual-class A and B share system from inception, preserving voting control for key holders.

Share distribution

All existing Novo Nordisk shareholders received Novozymes shares at the spin-off, maintaining investor continuity.

Anchor shareholder

Through Novo Holdings A/S, the Novo Nordisk Foundation became the anchor shareholder, controlling the A-share block from day one.

Protection clauses

Charter clauses were included to prevent hostile takeovers and protect the company’s founding mission and governance stability.

The early ownership mix featured concentrated Danish institutional capital and a dominant voting bloc held by the Foundation; there were no VC rounds, and the structure ensured continuity with Novo Nordisk as the effective parent via Novo Holdings A/S.

Founding ownership facts

Key data and implications for investors regarding Novozymes ownership and governance.

• Novozymes ownership began with a 2000 demerger from Novo Nordisk, preserving parent-like governance.
• The Novo Nordisk Foundation, via Novo Holdings A/S, controlled 100 percent of A-shares at inception.
• No venture capital funding rounds took place; initial capital and shareholders came from Novo Nordisk’s registry.
• Dual-class A/B shares established a governance model that continues to shape Novozymes corporate structure and board control.

Further reading on strategic positioning and corporate context is available in the article Marketing Strategy of Novozymes.

Novozymes SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The ownership of Novozymes shifted materially after the January 29, 2024 merger with Chr. Hansen, creating Novonesis and merging two legacy cap tables; by 2025 the group’s ownership is anchored by Novo Holdings A/S with a broadened international investor base and stabilized market cap near 35 billion EUR.

Primary ownership dynamics grant Novo Holdings a controlling voting position despite 25.5 percent of capital, enabling a patient capital model that supports R&D spend near 10 percent of annual revenue; the shareholder mix now skews global and ESG-focused, changing the Novozymes ownership profile and corporate structure.

Ownership Inflection: Merger Impact

The 2024 merger integrated Chr. Hansen holders into Novonesis and consolidated voting control under Novo Holdings, while institutional B-share investors increased international exposure.

• Novo Holdings remains the majority voting controller
• BlackRock and Capital Group are top B-share holders
• Pension funds like ATP retain meaningful stakes
• Market cap stabilized around 35 billion EUR in 2025

For deeper strategic context and historical analysis on Novozymes ownership evolution, see Growth Strategy of Novozymes.

Novozymes PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

Novonesis (formerly Novozymes) is overseen by a nine-member shareholder-elected board plus four employee-elected members, chaired by Cees de Jong with Jesper Brandgaard as Vice Chair; the board balances Nuevo Holdings' strategic influence and independent directors to align long-term R&D priorities with shareholder interests.

The company operates under a dual-class share capital: A-shares carry 10 votes each and B-shares carry 1 vote; Novo Holdings A/S owns all unlisted A-shares and thus controls over 70% of voting power while holding about 25% of economic ownership, insulating strategy from short-term activist pressure.

Board composition and voting control

The dual-class structure creates a large gap between voting power and equity stake, ensuring stable governance aligned with long-term research cycles.

• Dual-class shares: A (10 votes) vs B (1 vote)
• Novo Holdings controls > 70% of votes despite ~25% equity
• Board follows Danish Recommendations on Corporate Governance with majority independent members
• 2025 proxy season: no major voting contests; dividend policy targets 40–50% payout of net profit

For ownership history, corporate structure and investor-focused details see Revenue Streams & Business Model of Novozymes which contextualizes Novozymes ownership and Novozymes shareholders alongside recent governance changes.

Novozymes Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

From 2023–2025 Novozymes ownership evolved notably after the Chr. Hansen integration, with thematic institutional investors increasing stakes and the shareholder register stabilizing following post‑merger volatility.

Institutional ownership trends now show higher weightings from climate-transition and circular‑economy funds viewing Novonesis as a proxy for industrial decarbonization, while activist and retail shares remain steady.

Merger integration progress

Chr. Hansen investor base integrated; synergy target of €80m delivered in 2025, boosting investor confidence.

Shareholder register

Recent filings show stabilization after post‑merger fluctuation and no public privatization plans; Nasdaq Copenhagen listing retained for liquidity and talent attraction.

Capital allocation

Large buybacks paused during 2024 integration to preserve leverage; management signaled potential opportunistic buybacks in late 2025 as cash conversion improved above 90%.

Governance continuity

Departure of legacy executives (2024–2025) managed via a structured succession plan to preserve ownership strategic vision under CEO Ester Baiget.

For historical context on Novozymes ownership and corporate changes see Brief History of Novozymes.

Novozymes Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔